Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.87 |
| ▸ | F2 | P00734 | 17/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.74 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | F10 | P00742 | 1/20 | 0.72 |
| ▸ | PLG | P00747 | 1/20 | 0.72 |
| ▸ | PLAT | P00750 | 1/20 | 0.72 |
| ▸ | PROC | P04070 | 1/20 | 0.72 |
| ▸ | HPN | P05981 | 1/20 | 0.72 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.72 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.72 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.72 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.72 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746440 | 0.95 | NQO2 (0.84) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL28407707 | 0.95 | NQO2 (0.86) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL14696884 | 0.95 | NQO2 (0.86) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Hydrochloric Acid SCHEMBL14696875 | 0.94 | NQO2 (0.85) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL14696907 | 0.94 | NQO2 (0.90) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Dabigatran Ethyl Ester SCHEMBL29943705 | 0.93 | NQO2 (1.00) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL4757949 | 0.93 | NQO2 (0.89) | NQO2F2NR1I2ADORA3SLC6A2 | |
| Dabigatran Ethyl Ester SCHEMBL3027080 | 0.93 | NQO2 (1.00) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL10048254 | 0.93 | NQO2 (0.89) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL21451627 | 0.93 | NQO2 (0.85) | NQO2F2NR1I2ADORA3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050948-A1 | Process for the Synthesis of Dabigatran Etexilate and Its Intermediates | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-02-23 | — | — | US | disclosed |
| US-20170050948-A1 | Process for the Synthesis of Dabigatran Etexilate and Its Intermediates | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-02-23 | — | — | US | disclosed |
| US-20150246900-A1 | Process for the Synthesis of Dabigatran and Its Intermediates | Biophore India Pharmeuticals PVT. Ltd. (IN) | 2015-09-03 | — | — | US | disclosed |
| US-8455650-B2 | Benzimidazole derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8455650-B2 | Benzimidazole derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| US-8394961-B2 | Method for the preparation of dabigatran | ZENTIVA K.S. (CZ) | 2013-03-12 | — | — | US | disclosed |
| US-8394961-B2 | Method for the preparation of dabigatran | ZENTIVA K.S. (CZ) | 2013-03-12 | — | — | US | disclosed |
| US-20120116089-A1 | BENZIMIDAZOLE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-8119810-B2 | Process for the preparation of a benzimidazole derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20110306640-A1 | DABIGATRAN IN TUMOUR THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-15 | — | — | US | disclosed |
| US-20100099882-A1 | PROCESS FOR THE PREPARATION OF A BENZIMIDAZOLE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099882-A1 | PROCESS FOR THE PREPARATION OF A BENZIMIDAZOLE DERIVATIVE | TFPI, CYP3A4, CYP2E1 | NQO2 669/4885F2 22/4885NR1I2 1262/4885 |
| US-20120116089-A1 | BENZIMIDAZOLE DERIVATIVE | CYP3A4, TFPI, CYP2E1 | NQO2 361/4885F2 23/4885NR1I2 547/4885 |
| US-20110306640-A1 | DABIGATRAN IN TUMOUR THERAPY | TFPI, VHL, VKORC1 | NQO2 521/4885F2 12/4885NR1I2 1541/4885 |
| US-20170050948-A1 | Process for the Synthesis of Dabigatran Etexilate and Its Intermediates | TFPI, F7, F9 | NQO2 911/4885F2 9/4885NR1I2 2773/4885 |
| US-20150246900-A1 | Process for the Synthesis of Dabigatran and Its Intermediates | TFPI, VKORC1, VKORC1L1 | NQO2 334/4885F2 6/4885NR1I2 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.